Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | TNKS | O95271 | 7/20 | 0.56 |
| ▸ | TNKS2 | Q9H2K2 | 7/20 | 0.56 |
| ▸ | PARP1 | P09874 | 4/20 | 0.56 |
| ▸ | TOP2A | P11388 | 1/20 | 0.53 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.51 |
| ▸ | GUSB | P08236 | 8/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12351809 | 0.82 | HPGD (0.69) | HPGDKDM4EPKMTNKSTNKS2 | |
| SCHEMBL484134 | 0.79 | NPC1 (0.58) | HPGDKDM4EPKMALDH1A1MAPT | |
| SCHEMBL6695759 | 0.78 | TNKS2 (0.81) | HPGDKDM4EPKMTNKSTNKS2 | |
| SCHEMBL29502878 | 0.77 | PARP1 (0.51) | KDM4ETNKSTNKS2PARP1ALDH1A1 | |
| SCHEMBL18702980 | 0.77 | PARP1 (0.51) | KDM4ETNKSTNKS2PARP1ALDH1A1 | |
| SCHEMBL25921289 | 0.77 | HPGD (0.63) | HPGDKDM4EPKMTNKSTNKS2 | |
| SCHEMBL8787406 | 0.76 | ALDH1A1 (0.51) | HPGDKDM4EPKMALDH1A1MAPT | |
| SCHEMBL30362164 | 0.75 | HPGD (1.00) | HPGDKDM4EPKMTNKSTNKS2 | |
| SCHEMBL11830857 | 0.75 | HPGD (1.00) | HPGDKDM4EPKMTNKSTNKS2 | |
| SCHEMBL13700927 | 0.74 | ALDH1A1 (0.59) | HPGDKDM4EALDH1A1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED | 2009-12-24 | — | — | US | claimed |
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED | 2009-12-24 | — | — | US | disclosed |
| CN-101460490-A | Substituted ring fused azines and their use in cancer therapy | AUCKLAND UNISERVICES LTD (NZ) | 2009-06-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318479-A1 | SUBSTITUTED RING FUSED AZINES AND THEIR USE IN CANCER THERAPY | TP53, AZI2, MCL1 | HPGD 1540/4885KDM4E 221/4885PKM 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.